临床试验 以下为当前的临床试验。14 研究 CAR-T 细胞疗法计划 （仅限仍在招募的研究）. 按院区、状态和其他条件筛选该研究列表。 A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Rochester, Minn. A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Rochester, Minn. The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients Rochester, Minn., Jacksonville, Fla. The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients. Pagination 临床研究 PrevPrevious Page Go to page 11 Go to page 22 以下为当前的临床试验。14 研究 CAR-T 细胞疗法计划 （仅限仍在招募的研究）. 按院区、状态和其他条件筛选该研究列表。 A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Rochester, Minn. The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Rochester, Minn. A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients Rochester, Minn., Jacksonville, Fla. The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients. Pagination 临床研究 PrevPrevious Page Go to page 11 Go to page 22 申请预约 常见问题转诊 June 15, 2024 Share on: FacebookTwitterWeChatWeChatCloseWeibo CAR-T 细胞疗法计划科室首页部分概述关于 CAR-T 细胞疗法我们的项目医生常见问题临床试验转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士：妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者，提供以患者为中心的护理。在很多方面，这是一个循环。这个过程可能很简单，就是先在实验室里出现一个想法，然后带到病床旁加以实施，如果一切顺利，对患者有所助益， 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处，而这种以患者为中心的方式，也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述关于 CAR-T 细胞疗法我们的项目医生常见问题临床试验转诊 ORG-20404311 医学科室与中心 CAR-T 细胞疗法计划